Durvalumab vs Insulin Glargine

Durvalumab vs Insulin Glargine: Overview

This comparison examines the pharmacological differences between Durvalumab and Insulin Glargine.

Mechanism of Action

Durvalumab: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.

Insulin Glargine: Long-acting insulin analogue that binds insulin receptors.

Pharmacokinetics

Half-life: Durvalumab — 17 days; Insulin Glargine — 12-24 hours.

Chemical Properties

Type: Durvalumab — Antibody; Insulin Glargine — Protein.